TW202214241A - 心房功能障礙之治療 - Google Patents

心房功能障礙之治療 Download PDF

Info

Publication number
TW202214241A
TW202214241A TW110121782A TW110121782A TW202214241A TW 202214241 A TW202214241 A TW 202214241A TW 110121782 A TW110121782 A TW 110121782A TW 110121782 A TW110121782 A TW 110121782A TW 202214241 A TW202214241 A TW 202214241A
Authority
TW
Taiwan
Prior art keywords
patient
compound
atrial
atrial fibrillation
treatment
Prior art date
Application number
TW110121782A
Other languages
English (en)
Chinese (zh)
Inventor
珍 佛科斯 譚比
傑 Ｍ 愛德柏格
格雷戈里 霍華德 塔克爾 庫里歐
辛西婭 莉莉 凱莉
春 楊
馬克思 派崔克 亨茲
里歐 卡羅斯 Ｌ 迪歐
羅伯特 李 安德森
馬里烏斯 Ｐ 蘇曼達
吉騰德拉 甘吉
Original Assignee
美商邁奧卡迪亞公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商邁奧卡迪亞公司 filed Critical 美商邁奧卡迪亞公司
Publication of TW202214241A publication Critical patent/TW202214241A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
TW110121782A 2020-06-15 2021-06-15 心房功能障礙之治療 TW202214241A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063039438P 2020-06-15 2020-06-15
US63/039,438 2020-06-15
US202063042512P 2020-06-22 2020-06-22
US63/042,512 2020-06-22

Publications (1)

Publication Number Publication Date
TW202214241A true TW202214241A (zh) 2022-04-16

Family

ID=76845320

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110121782A TW202214241A (zh) 2020-06-15 2021-06-15 心房功能障礙之治療

Country Status (13)

Country Link
US (1) US20230233545A1 (enExample)
EP (1) EP4164644A1 (enExample)
JP (2) JP7832128B2 (enExample)
KR (1) KR20230024977A (enExample)
CN (1) CN116056703A (enExample)
AU (1) AU2021293817A1 (enExample)
BR (1) BR112022025551A2 (enExample)
CA (1) CA3180943A1 (enExample)
CL (1) CL2022003548A1 (enExample)
IL (1) IL298885A (enExample)
MX (1) MX2022015488A (enExample)
TW (1) TW202214241A (enExample)
WO (1) WO2021257456A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759640B2 (en) * 2022-01-07 2023-09-19 Xyra, Llc Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN119157623A (zh) * 2023-12-12 2024-12-20 成都迈格因科技有限公司 一种经导管心脏射频消融的蒸汽爆破安全预警和控制系统
CN117815534A (zh) * 2023-12-12 2024-04-05 苏州晟智医疗科技有限公司 反搏辅助装置、计算设备、存储介质及反搏系统
CN118304374A (zh) * 2024-04-01 2024-07-09 山东省中医药研究院附属医院 一种组合物在制备治疗心动过速和/或瓣膜反流药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021553074A1 (en) * 2015-01-22 2023-03-06 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
US10758525B2 (en) * 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
JP2020519628A (ja) * 2017-05-10 2020-07-02 インカーダ セラピューティクス， インコーポレイテッド 肺投与によって心臓の状態を処置するための単位用量、エアロゾル、キットおよび方法
LT3645002T (lt) * 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
CA3138080A1 (en) * 2019-05-19 2020-11-26 Jean-Francois TAMBY Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl) n-(isoxazol-3-yl)piperidine-1-carboxamid

Also Published As

Publication number Publication date
BR112022025551A2 (pt) 2023-03-07
CA3180943A1 (en) 2021-12-23
EP4164644A1 (en) 2023-04-19
MX2022015488A (es) 2023-03-21
AU2021293817A1 (en) 2023-01-19
JP7832128B2 (ja) 2026-03-17
CN116056703A (zh) 2023-05-02
CL2022003548A1 (es) 2023-06-09
US20230233545A1 (en) 2023-07-27
IL298885A (en) 2023-02-01
KR20230024977A (ko) 2023-02-21
WO2021257456A1 (en) 2021-12-23
JP2026048841A (ja) 2026-03-17
JP2023529502A (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
JP7832128B2 (ja) 心房機能不全の治療
US12616697B2 (en) Methods of treatment with myosin modulator
JP7830321B2 (ja) ミオシンモジュレーターによる治療方法
US20250241903A1 (en) Treatment of systolic dysfunction
RU2384346C2 (ru) Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора
HK40091633A (zh) 心房功能障碍的治疗
US20250325531A1 (en) Treatment of systolic dysfunction
HK40061292A (en) Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
HK40077232A (en) Methods of treatment with myosin modulator
EA052373B1 (ru) Способы лечения модулятором миозина
Mehta et al. Hypertensive Emergency